LB Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Selling, General & Admin	33.2	13.26	13.66	3.53	1.46
Research & Development	118.29	16.24	51.17	7.85	1.35
Operating Expenses	151.49	29.5	64.83	11.38	2.81
Operating Income	-151.49	-29.5	-64.83	-11.38	-2.81
Interest Expense	-	-	-	-4.83	-2.15
Interest & Investment Income	12.4	3.92	1.72	0.81	0.07
Other Non Operating Income (Expenses)	-1.21	1.16	-0.95	16.22	-9.46
EBT Excluding Unusual Items	-140.3	-24.42	-64.06	0.83	-14.35
Merger & Restructuring Charges	-0.9	-0.9	-	-	-
Gain (Loss) on Sale of Investments	0	0.12	0.96	0.33	0
Other Unusual Items	-	-	-	-7.44	-
Pretax Income	-141.19	-25.2	-63.1	-6.27	-14.35
Income Tax Expense	0	0	0	0	0
Net Income	-141.2	-25.21	-63.1	-6.28	-14.35
Net Income to Common	-141.2	-25.21	-63.1	-6.28	-14.35
Net Income Growth	-	-	-	-	-
Shares Outstanding (Basic)	29	8	0	0	0
Shares Outstanding (Diluted)	29	8	0	0	0
Shares Change	1602.13%	2145.81%	43.52%	8.02%	-
EPS (Basic)	-4.82	-3.13	-176.15	-25.14	-62.09
EPS (Diluted)	-4.82	-3.13	-176.15	-25.14	-62.09
EPS Growth	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Free Cash Flow	-143.82	-35.26	-53.82	-12.12	-2.73
Free Cash Flow Per Share	-4.91	-4.38	-150.24	-48.55	-11.80
EBITDA	-151.1	-29.18	-64.74	-11.37	-2.81
D&A For EBITDA	0.39	0.32	0.09	0	0
EBIT	-151.49	-29.5	-64.83	-11.38	-2.81

SEC Filings: 10-K · 10-Q